ArticleScientific reports2025
Optimizing shared decision-making for risk-reducing mastectomy in women with Li-Fraumeni syndrome using patient-reported outcome measures.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Decisions regarding risk-reducing mastectomy (RRM) in women with Li-Fraumeni Syndrome (LFS) are challenged by unclear survival benefits and potential quality of life (QOL) impacts. We evaluated QOL in LFS women and identified factors associated with QOL outcomes in those who received RRM. LFS women from a single institution cohort between 2012 and 2022 were identified and BREAST-Q surveys were administered. Scores were compared according to the choice of RRM or surveillance and factors associated with differences in QOL outcomes in patients submitted to RRM were identified. Among 90 women, 37 (41%) chose surveillance and 53 (59%) underwent RRM. Compared to surveillance, RRM women had worse satisfaction with breasts (p = 0.05) and physical well-being (p < 0.01) scores. RRM ≤ 30 years was associated with worse psychosocial well-being (p = 0.05). Women with no cancer and breast cancer only had worse sexual health than those with other malignancies (p = 0.02). Sentinel lymph node biopsy (SLNB) at RRM was associated with lower psychosocial (p = 0.05) and satisfaction (p = 0.01) scores. Implant-based was superior to autologous reconstruction in sexual well-being (p = 0.05). Surgical complications resulted in worse sexual (p = 0.05) and physical (p = 0.04) outcomes, while additional reconstructive surgery resulted in worse psychosocial (p = 0.01), sexual (p < 0.01), and physical (p < 0.01) well-being. RRM resulted in worse satisfaction with breasts and physical well-being than surveillance. Age at RRM, oncological history, financial status, SLNB, surgical complications, and additional breast reconstructive surgery were associated with differences in QOL in women with RRM. These findings add valuable insights for breast cancer risk management in LFS women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.